Loblaw finds a new growth engine
Loblaw Companies, Canada's biggest grocery and pharmacy chain, is leaning into a business that didn't even exist for most Canadians a few years ago: generic versions of GLP-1 drugs, the class of medications that includes blockbuster weight-loss and diabetes treatments like Ozempic and Wegovy.
The company says sales of these generic alternatives are up 40 per cent year-to-date, a jump that's helping boost overall profit even as everyday grocery shopping habits shift.
Why generics are booming
Brand-name GLP-1 drugs have carried eye-watering price tags since they exploded in popularity, driven by demand for both diabetes management and weight loss. As patents and exclusivity windows have opened up room for generic competitors, pharmacies like Shoppers Drug Mart — owned by Loblaw — have been positioned to sell cheaper versions to Canadians who couldn't otherwise afford the brand names.
For a company with a massive national pharmacy network, that's a significant new revenue stream layered on top of its traditional grocery business.
Bargain hunting shoppers, too
The GLP-1 boost isn't the whole story. Loblaw also points to bargain-hunting behaviour among Canadian shoppers as a factor in its latest results. With grocery prices still a sore spot for household budgets across the country, more Canadians have been leaning on discount banners, loyalty programs, and private-label products to stretch their dollars — and Loblaw, which owns budget-friendly chains alongside its full-service stores, is well-positioned to capture that shift.
Together, the combination of higher-margin pharmacy sales and value-conscious grocery shopping has helped the company post stronger profits, even as affordability remains a major concern for many Canadian families.
The bigger picture
Loblaw's results offer a snapshot of two trends reshaping retail in Canada right now: the rapid mainstreaming of GLP-1 medications as more affordable generics hit the market, and a grocery sector where shoppers are increasingly price-sensitive after years of elevated food costs.
For a company that operates both pharmacies and grocery stores under one roof, those two forces are turning out to be complementary rather than competing — with cost-conscious shoppers filling carts with discounted staples in one aisle, while pharmacy counters see rising demand for cheaper weight-loss and diabetes drugs.
As more generic GLP-1 options continue to roll out across Canada, expect pharmacy chains to keep highlighting this segment as a bright spot in future earnings reports.
Source: CBC Business
